Market Closed -
Nasdaq
04:00:00 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
34.65
USD
|
+4.18%
|
|
+10.49%
|
-15.82%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,574
|
4,090
|
4,343
|
1,821
|
2,799
|
2,371
|
-
|
-
|
Enterprise Value (EV)
1 |
1,567
|
3,505
|
4,237
|
611.1
|
1,539
|
1,435
|
1,788
|
1,824
|
P/E ratio
|
-19.3
x
|
-28.1
x
|
-21.5
x
|
-6.44
x
|
-6.22
x
|
-9.21
x
|
-7.72
x
|
-9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
36.6
x
|
188
x
|
93
x
|
13.9
x
|
35.7
x
|
13
x
|
10.8
x
|
8.14
x
|
EV / Revenue
|
36.5
x
|
161
x
|
90.7
x
|
4.65
x
|
19.6
x
|
7.87
x
|
8.15
x
|
6.26
x
|
EV / EBITDA
|
-31.4
x
|
-28.8
x
|
-22.2
x
|
-2.38
x
|
-3.88
x
|
-4.23
x
|
-5.37
x
|
-5.19
x
|
EV / FCF
|
-33.4
x
|
-36.4
x
|
7.64
x
|
-2.18
x
|
-4.39
x
|
-7.35
x
|
-6.14
x
|
-7.17
x
|
FCF Yield
|
-2.99%
|
-2.75%
|
13.1%
|
-45.9%
|
-22.8%
|
-13.6%
|
-16.3%
|
-13.9%
|
Price to Book
|
-
|
-
|
5.57
x
|
3.22
x
|
3.46
x
|
6.38
x
|
57.9
x
|
18.5
x
|
Nbr of stocks (in thousands)
|
38,304
|
48,158
|
52,872
|
53,228
|
67,999
|
68,432
|
-
|
-
|
Reference price
2 |
41.09
|
84.93
|
82.14
|
34.21
|
41.16
|
34.65
|
34.65
|
34.65
|
Announcement Date
|
3/16/20
|
3/1/21
|
2/28/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
42.98
|
21.8
|
46.7
|
131.4
|
78.5
|
182.4
|
219.4
|
291.2
|
EBITDA
1 |
-49.96
|
-121.7
|
-190.5
|
-256.9
|
-396.7
|
-339.5
|
-333
|
-351.6
|
EBIT
1 |
-51.52
|
-124.9
|
-195.3
|
-263.2
|
-401.5
|
-310.6
|
-340
|
-310
|
Operating Margin
|
-119.89%
|
-572.69%
|
-418.2%
|
-200.3%
|
-511.46%
|
-170.36%
|
-154.92%
|
-106.48%
|
Earnings before Tax (EBT)
1 |
-70.29
|
-119.3
|
-191
|
-261.6
|
-363.9
|
-264.9
|
-327.9
|
-291.2
|
Net income
1 |
-70.29
|
-119.3
|
-191
|
-282.5
|
-367.3
|
-255.9
|
-306.6
|
-283.8
|
Net margin
|
-163.56%
|
-547.35%
|
-408.99%
|
-214.99%
|
-467.9%
|
-140.35%
|
-139.71%
|
-97.49%
|
EPS
2 |
-2.130
|
-3.020
|
-3.820
|
-5.310
|
-6.620
|
-3.763
|
-4.489
|
-3.851
|
Free Cash Flow
1 |
-46.87
|
-96.2
|
554.7
|
-280.3
|
-350.7
|
-195.3
|
-291.1
|
-254.3
|
FCF margin
|
-109.06%
|
-441.27%
|
1,187.79%
|
-213.32%
|
-446.75%
|
-107.09%
|
-132.67%
|
-87.35%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/16/20
|
3/1/21
|
2/28/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
26.3
|
24.2
|
31.3
|
30.3
|
38
|
32.5
|
54.5
|
34.6
|
-43.1
|
25.3
|
70.52
|
43.3
|
44.65
|
37.8
|
40.1
|
EBITDA
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-164.1
|
-82.1
|
-78.26
|
-93.5
|
-98.36
|
-
|
-
|
EBIT
1 |
-54.4
|
-60
|
-68.3
|
-67.2
|
-75.4
|
-87.7
|
-74.6
|
-73.9
|
-165.3
|
-83.3
|
-50.39
|
-76.95
|
-91.68
|
-99.68
|
-103.6
|
Operating Margin
|
-206.84%
|
-247.93%
|
-218.21%
|
-221.78%
|
-198.42%
|
-269.85%
|
-136.88%
|
-213.58%
|
383.53%
|
-329.25%
|
-71.46%
|
-177.71%
|
-205.31%
|
-263.72%
|
-258.22%
|
Earnings before Tax (EBT)
1 |
-53
|
-58.9
|
-66.6
|
-64
|
-72.1
|
-81.2
|
-65.6
|
-63.9
|
-153.2
|
-69.3
|
-36.66
|
-69.06
|
-90.98
|
-98.98
|
-104.4
|
Net income
1 |
-53
|
-63.4
|
-70
|
-66.2
|
-82.9
|
-81.9
|
-66.6
|
-64
|
-154.8
|
-69.4
|
-33.28
|
-70.79
|
-82.76
|
-82.18
|
-87.76
|
Net margin
|
-201.52%
|
-261.98%
|
-223.64%
|
-218.48%
|
-218.16%
|
-252%
|
-122.2%
|
-184.97%
|
359.16%
|
-274.31%
|
-47.19%
|
-163.47%
|
-185.33%
|
-217.43%
|
-218.83%
|
EPS
2 |
-1.000
|
-1.200
|
-1.320
|
-1.240
|
-1.560
|
-1.540
|
-1.250
|
-1.180
|
-2.530
|
-0.9700
|
-0.5048
|
-0.9946
|
-1.117
|
-1.163
|
-1.167
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/22
|
5/5/22
|
8/4/22
|
11/8/22
|
2/23/23
|
5/5/23
|
8/8/23
|
11/7/23
|
2/27/24
|
5/7/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
7.21
|
585
|
106
|
1,210
|
1,260
|
936
|
583
|
547
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-46.9
|
-96.2
|
555
|
-280
|
-351
|
-195
|
-291
|
-254
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-26.8%
|
-42%
|
-60%
|
-59%
|
-94.7%
|
-134%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
14.70
|
10.60
|
11.90
|
5.430
|
0.6000
|
1.880
|
Cash Flow per Share
2 |
-
|
-
|
11.20
|
-5.140
|
-6.270
|
0.5200
|
0.6200
|
-
|
Capex
1 |
6.24
|
6.45
|
4.7
|
6.8
|
2.9
|
5.09
|
12.9
|
18.2
|
Capex / Sales
|
14.53%
|
29.57%
|
10.06%
|
5.18%
|
3.69%
|
2.79%
|
5.86%
|
6.25%
|
Announcement Date
|
3/16/20
|
3/1/21
|
2/28/22
|
2/23/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
34.65
USD Average target price
68.44
USD Spread / Average Target +97.53% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.82% | 2.28B | | +8.63% | 115B | | +13.17% | 107B | | -12.76% | 22.31B | | -3.99% | 21.6B | | -7.19% | 18.23B | | -39.93% | 17.62B | | +6.67% | 14.26B | | +33.90% | 12.37B | | -28.60% | 8.28B |
Bio Therapeutic Drugs
|